JPH03161432A - Cataplasm - Google Patents
CataplasmInfo
- Publication number
- JPH03161432A JPH03161432A JP30130089A JP30130089A JPH03161432A JP H03161432 A JPH03161432 A JP H03161432A JP 30130089 A JP30130089 A JP 30130089A JP 30130089 A JP30130089 A JP 30130089A JP H03161432 A JPH03161432 A JP H03161432A
- Authority
- JP
- Japan
- Prior art keywords
- modulus
- substrate
- cataplasm
- plaster
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011505 plaster Substances 0.000 claims abstract description 16
- 239000004753 textile Substances 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 6
- 239000004744 fabric Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract 4
- 239000002674 ointment Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 19
- 239000004745 nonwoven fabric Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- -1 polyethylene Polymers 0.000 description 8
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920001169 thermoplastic Polymers 0.000 description 5
- 239000004416 thermosoftening plastic Substances 0.000 description 5
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 4
- 229910001701 hydrotalcite Inorganic materials 0.000 description 4
- 229960001545 hydrotalcite Drugs 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 229960003338 crotamiton Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960002389 glycol salicylate Drugs 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 description 3
- 239000002964 rayon Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229960000962 bufexamac Drugs 0.000 description 2
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用
本発明はパップ剤、プラスター剤などとして用いられる
貼付剤に関する,
災来汝挟亙
従来から、皮膚に適用される貼付剤として、バップ剤、
プラスター剤が繁用されている。特にバップ剤は近年研
究が進み,粘着力の大きな含水ゲル膏体が開発され、粘
着テープ等で皮膚に固定する必要がなくなった(特開昭
59−110617号公報、同59−13718号公報
)。[Detailed description of the invention] Industrial application The present invention relates to a patch used as a poultice, a plaster, etc. Conventionally, the patch used as a poultice, a plaster, etc. has been used as a patch to be applied to the skin.
Plasters are frequently used. In particular, research into poultices has progressed in recent years, and hydrogel plasters with high adhesive strength have been developed, eliminating the need for fixing them to the skin with adhesive tape, etc. (Japanese Patent Laid-Open Nos. 59-110617 and 59-13718). .
しかし、従来のパップ剤に支持体として使用されている
リント布や不織布は,それ自体ほとんど伸縮性をもたな
いため,一貼付した場合に人体の皮膚の動きに追随でき
ず、及膚より剥離してしまうことが応々にしてあった。However, the lint cloth and non-woven fabric used as a support for conventional poultices have almost no elasticity, so when applied once, they cannot follow the movement of the human skin and may peel off from the skin. There were many things I ended up doing.
そこでこの問題を解決するために、伸縮性の不織布や伸
縮性のメリヤス布を使ったパップ剤が開発されている(
特開昭63−122621号公報、特開平1−1212
14号公報、同1−197434号公報、同1−228
911号公報).
しかしながら、これらの伸縮性支持体を用いた場合であ
っても、肘、膝などにはある程度の追随性を示すが,首
すじ、脇腹など皮膚が複雑な動きをする部位での追随性
が悪く、剥離しやすいという問題があった.
明が しようとする
本発明は、首すじ、脇腹などの複雑な動きをする部位で
も、優れた追随性を示す貼付剤を提供するものである。To solve this problem, poultices using stretchable non-woven fabrics or stretchable knitted fabrics have been developed (
JP-A-63-122621, JP-A-1-1212
Publication No. 14, Publication No. 1-197434, Publication No. 1-228
Publication No. 911). However, even when these elastic supports are used, although they show some degree of tracking ability in areas such as elbows and knees, they have poor tracking ability in areas where the skin makes complex movements, such as the neck and flanks. The problem was that it peeled off easily. The purpose of the present invention is to provide a patch that exhibits excellent followability even in areas that undergo complex movements, such as the neck and flanks.
見週J月橿虜
本発明の貼付剤は、支持体部および膏体部を有する貼付
剤において、支持体部として、50%モジュラスが0.
1−2.0kg/ 5cmであり、かつ、JIS一般織
物試験法による剛軟性がドレープ係数で0.200〜0
.650である伸縮性支持体を用いたことを特徴とする
。The patch of the present invention has a support part and a plaster part, and the support part has a 50% modulus of 0.
1-2.0kg/5cm, and the drape coefficient is 0.200 to 0 according to the JIS general textile test method.
.. It is characterized by using a stretchable support made of No. 650.
以下、本発明についてさらに詳細に説明する。The present invention will be explained in more detail below.
人体でも肘、膝,首などの皮膚は、特に伸縮性が高く、
これらの部位の伸縮率は最大1.4〜1.5倍に達する
。したがって,これらの部位に貼付される貼付剤の支持
体は、元の長さの最大1.5倍までの伸長率が要求され
る。また,この最大伸びである1.5倍(50%の伸び
)の長さに引き伸ばすための荷重(50%モジュラス)
の値は、膏体そのものの粘着力によっても異なるが、で
きるだけ小さい方が望ましい。しかし一方において、5
0%モジュラス値が小さくなり過ぎると、強度が低下し
たり、膏体塗工時の適性が悪くなる。そこで,本発明で
は、50%モジュラスが0.1−2.0kg/5cm、
好ましくは0.1−0.8kg/ 5cmの支持体が用
いられる。なお、本発明の支持体は縦方向のみがこのモ
ジュラス値を満足していても、縦、横両方向(全方向)
がこの値を満足していてもよく、後者が望ましい。Even in the human body, the skin on elbows, knees, neck, etc. has particularly high elasticity.
The expansion/contraction rate of these parts reaches a maximum of 1.4 to 1.5 times. Therefore, the support for the patch applied to these areas is required to have an elongation rate of up to 1.5 times its original length. Also, the load (50% modulus) to stretch the length to 1.5 times the maximum elongation (50% elongation)
Although the value of will vary depending on the adhesive strength of the plaster itself, it is desirable that it be as small as possible. But on the other hand, 5
If the 0% modulus value becomes too small, the strength will decrease and the suitability for plaster coating will deteriorate. Therefore, in the present invention, the 50% modulus is 0.1-2.0 kg/5 cm,
Preferably a support of 0.1-0.8 kg/5 cm is used. Note that even if the support of the present invention satisfies this modulus value only in the vertical direction, it can be used in both the vertical and horizontal directions (all directions).
may satisfy this value, and the latter is preferable.
50%モジュラス値は,以下のようにして測定される。The 50% modulus value is measured as follows.
すなわち、50mm X 300mmの試片につき抗張
力試験機を用い,試長200mm、引張速度200mm
/minで100■まで引き伸ばし、この強度(kg)
を測定し50%モジュラスとする。That is, using a tensile strength testing machine for a 50 mm x 300 mm specimen, the test length was 200 mm, and the tensile speed was 200 mm.
/min to 100cm, this strength (kg)
is measured and taken as the 50% modulus.
しかし、上記50%モジュラス値を満足するだけでは本
発明の効果を得ることはできない。首すじ、脇腹など皮
膚が軟らかく、複雑な動きをする部位では、支持体に伸
縮性を与えるだけでは十分な追随性が得られない。そこ
で、本発明では伸縮性に加え、支持体に適度の柔軟性を
付与することにより、上記の追随性を改善したものであ
り. JIS一般織物試験法(JIS L 1096−
1979)による剛軟性がドレープ係数で0. 200
〜0.650、好ましくは0.250〜0.450の支
持体を用いる。ドレープ係数が0.650を超えると柔
軟性が悪く、皮膚への追随性が十分でない。一方、ドレ
ープ係数が0. 200未満では柔らかすぎて、皮膚へ
貼付する時に貼りにくく、使用性が悪くなる.上記の条
件を満足する支持体の種類としては、織布、編布、不織
布,高分子フィルムまたはこれらの積層体等いずれでも
良いが、特に不織布または不織布と高分子フィルムとの
積層体が好ましい。不織布の素材は特に限定されないが
、熱可塑性繊維単独または熱可塑性繊維と非熱可塑性繊
維の混紡であることが望ましい。また、高分子フィルム
としては、ウレタン系高分子フィルムが好ましい。However, the effects of the present invention cannot be obtained only by satisfying the above 50% modulus value. In areas where the skin is soft and makes complex movements, such as the neck and flanks, sufficient followability cannot be obtained simply by providing elasticity to the support. Therefore, in the present invention, the above-mentioned conformability is improved by imparting appropriate flexibility to the support in addition to stretchability. JIS general textile testing method (JIS L 1096-
(1979), the drape coefficient is 0. 200
~0.650, preferably 0.250-0.450 support is used. When the drape coefficient exceeds 0.650, the flexibility is poor and the followability to the skin is insufficient. On the other hand, the drape coefficient is 0. If it is less than 200, it is too soft and difficult to apply to the skin, resulting in poor usability. The type of support that satisfies the above conditions may be any of woven fabrics, knitted fabrics, nonwoven fabrics, polymer films, or laminates thereof, but nonwoven fabrics or laminates of nonwoven fabrics and polymer films are particularly preferred. The material of the nonwoven fabric is not particularly limited, but it is desirable to use thermoplastic fibers alone or a blend of thermoplastic fibers and non-thermoplastic fibers. Further, as the polymer film, a urethane polymer film is preferable.
熱可塑性繊維としては、ポリエステル繊維、ポリエチレ
ン繊維、ポリプロピレン繊維,ボリアミド繊維、ポリ塩
化ビニル繊維,ポリビニルアルコール繊維などが挙げら
れ、これらは単独で、または2種以上混合して用いられ
る。非熱可塑性繊維しては、レーヨン、キュポラ、麻、
絹などが挙げられる。Examples of thermoplastic fibers include polyester fibers, polyethylene fibers, polypropylene fibers, polyamide fibers, polyvinyl chloride fibers, and polyvinyl alcohol fibers, which may be used alone or in combination of two or more. Non-thermoplastic fibers include rayon, cupola, hemp,
Examples include silk.
これらの繊維を用いて不織布を製造する方法は、特に限
定されないが、例えば、熱収縮率の異なる2種の繊維を
貼り合わせた繊維を、二ドルパンチ法、スパンレース法
などにより交終一体化し、加熱処理により熱収縮を起こ
させて伸縮性とする方法がある。特にドレープ係数を小
さくするためには、スバンレース法が好ましい。The method for producing a nonwoven fabric using these fibers is not particularly limited, but for example, two types of fibers with different heat shrinkage rates are pasted together and integrated by a double punch method, a spunlace method, etc. There is a method of causing thermal contraction through heat treatment to make it stretchable. In particular, in order to reduce the drape coefficient, the Suban lace method is preferable.
本発明の貼付剤の膏体としては、従来使用されている膏
体、例えば薬効戊分,水溶性高分子、鉱物性粉末、硬化
剤および水を十分に練り合わせたものが利用できる。As the paste for the patch of the present invention, conventionally used pastes, such as those prepared by sufficiently kneading medicinal extracts, water-soluble polymers, mineral powders, hardeners, and water, can be used.
薬効成分としては特に限定されないが、例えば、サリチ
ル酸メチル,サリチル酸グリコール、インドメタシン、
ケトプロフェン、フルルビプロフェン、イブプロフェン
、ジクロフェナックナトリウム、メフェプム酸とその誘
導体、フルフェナム酸とその誘導体、ブフェキサマック
、イブフエナック、アルクロフェナック、プレドニゾロ
ン、酢酸ヒドロコルチゾン、デキタメゾン、悲一メント
ール、dQ一カンフル、クロタミトン、塩酸ジフェンヒ
ドラミン、マレイン酸クロルフェニラミン、酢酸トコフ
ェロール、ノニル酸ワニリルアミド、ナプロキセン、ピ
ロキシカム、カプサイシン、オオバクなどの生薬末、ト
ウガラシエキスなどの生薬軟エキス、オオバク乾燥エキ
スなどの生薬乾燥エキス,センブリ流エキスなどの生薬
流エキス,アルニカチンキなどの生薬チンキ、ハッカ油
、ケイ皮油などの精油などがある。The medicinal ingredients are not particularly limited, but include, for example, methyl salicylate, glycol salicylate, indomethacin,
Ketoprofen, flurbiprofen, ibuprofen, diclofenac sodium, mefepmic acid and its derivatives, flufenamic acid and its derivatives, bufexamac, ibufenac, alclofenac, prednisolone, hydrocortisone acetate, dekitamesone, Shinichi menthol, dQ camphor, crotamiton , diphenhydramine hydrochloride, chlorpheniramine maleate, tocopherol acetate, vanillylamide nonylic acid, naproxen, piroxicam, capsaicin, powdered crude drugs such as Vasperica nigra, soft extracts of herbal medicines such as capsicum extract, dried extracts of crude drugs such as Dried extract of Macaroni spp., etc. These include herbal medicine extracts, herbal medicine tinctures such as arnica tincture, and essential oils such as peppermint oil and cinnamon bark oil.
水溶性高分子としては、ゼラチン、ペクチン、ポリアク
リル酸、ポリアクリル酸ナトリウム、ポリビニルアルコ
ール、ポリビニルピロリドン、ポリビニルピロリドン・
ビニルアセテート共重合体、ポリエチレンオキサイド、
カルボキシメチルセルロースナトリウム、ヒドロキシプ
口ピルセルロース、メチルセルロース、アルギン酸ナト
リウム、キサンタンガム、アルビアガム、トラガントガ
ム、カラヤガム、メチノレビニノレエーテル、焦水マレ
イン酸共重合体などが挙げられる。Water-soluble polymers include gelatin, pectin, polyacrylic acid, sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone,
vinyl acetate copolymer, polyethylene oxide,
Examples include sodium carboxymethylcellulose, hydroxybutylated cellulose, methylcellulose, sodium alginate, xanthan gum, gum albia, gum tragacanth, gum karaya, methinolevinolether, and pyrohydric maleic acid copolymer.
鉱物性粉末としては、例えば、カオリン、ベントナイト
、モンモリ口ナイト、酸化亜鉛、酸化チタン、無水ケイ
酸などが挙げられる。Examples of the mineral powder include kaolin, bentonite, montmolystite, zinc oxide, titanium oxide, and silicic anhydride.
硬化剤としては,硫酸アルミニウムカリウム、ケイ酸ア
ルミン酸マグネシウム、水酸化アルミニウム、水酸化ア
ルミナマグネシウム、メタケイ酸アルミン酸マグネシウ
ム、合成ヒドロタルサイト,ジヒドロキシアルミニウム
アミノアセテートなどが挙げられる。Examples of the hardening agent include potassium aluminum sulfate, magnesium aluminate silicate, aluminum hydroxide, magnesium alumina hydroxide, magnesium aluminate metasilicate, synthetic hydrotalcite, dihydroxyaluminum aminoacetate, and the like.
この他、グリセリン、ソルビトール、プロピレングリコ
ール等の保湿剤、ポリソルベート80、ポリオキシエチ
レン硬化ヒマシ油、グリセリン脂肪酸エステル等の界面
活性剤を配合することができる。In addition, humectants such as glycerin, sorbitol, and propylene glycol, and surfactants such as polysorbate 80, polyoxyethylene hydrogenated castor oil, and glycerin fatty acid esters can be blended.
また,本発明の貼付剤は,支持体が伸縮性である利点を
十二分生かすために、膏体の粘着力が十分強いことが望
ましく、ポールタック法粘着力でNα4以上,好ましく
はNα10以上であることが望ましい。In addition, in the patch of the present invention, in order to take full advantage of the elasticity of the support, it is desirable that the adhesive strength of the plaster is sufficiently strong, and the adhesive strength by pole tack method is Nα4 or more, preferably Nα10 or more. It is desirable that
本発明の貼付剤は、前述の支持体に公知の方法により膏
体を塗工することにより製造することができる。The adhesive patch of the present invention can be produced by applying a plaster to the above-mentioned support by a known method.
見映立立果
本発明によれば、50%モジュラスが0.1〜2.0k
g/cm.かつ、ドレープ係数0. 200 〜0.6
50の支持体を用いることにより、関節部、首すじ、脇
腹など人体の動きが激しく、また,動きの複雑な部位に
貼付しても、皮膚の動きに追随することができるため、
皮膚から剥離しにくく密着性に優れ、膏体の冷却効果お
よび有効成分の吸収性に優れた治療効果の高い貼付剤が
得られる。According to the present invention, the 50% modulus is 0.1 to 2.0k.
g/cm. And the drape coefficient is 0. 200 ~0.6
By using 50 supports, it can follow the movement of the skin even when applied to areas where the human body moves rapidly or complexly, such as joints, neck, flanks, etc.
A highly therapeutically effective patch is obtained that is difficult to peel off from the skin, has excellent adhesion, has a cooling effect as a plaster, and has excellent absorption of active ingredients.
(以下余白)
実施例エ
サリチル酸グリコール
Q−メントール
dQ一カンフノレ
カオリン
グリセリン
プロピレングリコール
ポリソルベート80
合成ヒドロタルサイト
7,0
20.0
10.0
1.0
0.06
100.0
※1)
固形分として4.0%
ポリエステル繊維100%の不布織で、50%モジュラ
ス0.5Kg/5cm. ドレープ係数0.382の
支持体に、上記組成の膏体を常法により練合し、工枚(
140 X 100mm)当たり16gとなるように塗
工、裁断して、本発明の貼付剤を得た。(Leaving space below) Example Glycol esalicylate Q-Menthol dQ-Camfunorekaolin Glycerin Propylene glycol polysorbate 80 Synthetic hydrotalcite 7.0 20.0 10.0 1.0 0.06 100.0 *1) As solid content 4.0% non-woven fabric of 100% polyester fiber, 50% modulus 0.5Kg/5cm. A plaster of the above composition is kneaded on a support with a drape coefficient of 0.382 by a conventional method to form a workpiece (
The patch of the present invention was obtained by coating and cutting the adhesive to give a weight of 16 g per 140 mm x 100 mm.
比較例エ
ポリエステル繊維100%の不織布で、50%モジュラ
ス0.4kg/5cm. ドレープ係数0.182の
支持体に、実施例工と同じ膏体を同様に塗工、裁断し比
較例1を得た.
比較例2
ポリエステル繊維95%,レーヨン5%の不織布で,5
0%モジュラス0.8kg/ 5 cm. ドレープ
係数0.728の支持体に5実施例lと同じ膏体を同様
に塗工、裁断し比較例2を得た。Comparative Example A non-woven fabric made of 100% epoxy fiber, with a 50% modulus of 0.4 kg/5 cm. Comparative Example 1 was obtained by coating and cutting the same plaster as in Example onto a support having a drape coefficient of 0.182. Comparative Example 2 A nonwoven fabric of 95% polyester fiber and 5% rayon.
0% modulus 0.8 kg/5 cm. Comparative Example 2 was obtained by applying the same paste as in Example 5 to a support having a drape coefficient of 0.728 and cutting it in the same manner.
比較例3
ポリエステル繊維50%、レーヨン50%の全く伸びな
い不織布で、ドレープ係数0.352の支持体に,実施
例1と同じ膏体を同様に塗工、裁断し比較例3を得た。Comparative Example 3 Comparative Example 3 was obtained by applying the same paste as in Example 1 to a support made of a completely non-stretchable nonwoven fabric of 50% polyester fiber and 50% rayon and having a drape coefficient of 0.352, and cutting it in the same manner as in Example 1.
実験例1(使用テスト)
健常男子10人を選び、実施例1、比較例1、比較例2
および比較例3を順に左側首すじに(首から肩にかけて
)貼付し、その際の貼りやすさを評価した。さらに、貼
付してから5時間後に剥離の状態をamし,以上の結果
を下記表一↓に示した。Experimental Example 1 (Usage Test) Select 10 healthy men and conduct Example 1, Comparative Example 1, and Comparative Example 2.
and Comparative Example 3 were sequentially applied to the left side of the neck (from the neck to the shoulder), and the ease of application was evaluated. Furthermore, the state of peeling was examined 5 hours after application, and the results are shown in Table 1 below.
りやすさの 基゛
貼りやすい :0
どちらとも言えない:Δ
貼りにくい :×
剥れにくさの 基゜
全く剥れない :O
周囲がややめくれ上がる:O
半分以上が剥れる :Δ
剥れ落ちる :×
(以下余白)
剥れ:剥れにくさについての評価結果
実験例2
実験例1を終了した後、剥したサンプルを回収し、膏体
中のサリチル酸グリコールの残量を測定するとにより、
サリチル酸グリコールの皮膚への吸収量を比較した。そ
の結果を表−2に示した.
(以下余白)
表−2
上記表−lの結果より、本発明の貼付剤は貼りやすさ、
剥れにくさの両面から優れていることが判る。Base of ease of peeling: 0 Cannot say: Δ Difficult to stick: × Base of difficulty in peeling: Does not peel off at all: O Slightly curly edges: O More than half peels off: Δ Peels off: × (blank below) Peeling: Evaluation results for resistance to peeling Experimental example 2 After completing Experimental example 1, the peeled samples were collected and the remaining amount of glycol salicylate in the plaster was measured.
The amount of glycol salicylate absorbed into the skin was compared. The results are shown in Table 2. (Space below) Table 2 From the results in Table 1 above, the adhesive patch of the present invention is easy to apply,
It can be seen that it is excellent in terms of resistance to peeling.
また,表−2より、本発明の貼付剤は密着性に優れてい
るため、有効或分の吸収が良く、高い有効性を示すこと
が確認できた。比較例↓は、50%モジュラスが低いが
、ドレープ係数も低いため,密着性は良いが,柔軟すぎ
て使用時に貼りにくいという欠点が明らかとなった。Furthermore, from Table 2, it was confirmed that the adhesive patch of the present invention has excellent adhesion, has good absorption to a certain extent, and exhibits high effectiveness. Comparative example ↓ had a low 50% modulus and a low drape coefficient, so it had good adhesion, but it became clear that it was too flexible and difficult to stick during use.
以上のように本発明の効果は,50%モジュラスとドレ
ープ係数の両方を満足する支持体を用いることにより初
めて達成されるものであり、このどちらか一方が欠けて
も達成できないものである。As described above, the effects of the present invention can only be achieved by using a support that satisfies both 50% modulus and drape coefficient, and cannot be achieved even if either one of them is lacking.
実施例2
膏 組
インドメタシン
悲−メントール
クロタミトン
ポリビニルアルコール
カオリン
グリセリン
プロピレングリコール
ボリソルベート80
合或ヒドロタルサイト
水
※1)
固形分として4.0%
1.0
7.0
20.0
10.0
1.0
0,05
100.0
ポリエステル繊維75%、ポリプロピレン繊維25%の
混紡の不織布で、50%モジュラス0.48kg/5c
m、ドレープ係数0.338の支持体に、上記組成の膏
体を1枚(140 X 100mm)当たり17gとな
るように塗工,裁断し、本発明の貼付剤を得た。Example 2 Plasma: Indomethacin, menthol, crotamiton, polyvinyl alcohol, kaolin, glycerin, propylene glycol, polysorbate, 80% hydrotalcite water *1) 4.0% as solids 1.0 7.0 20.0 10.0 1. 0 0,05 100.0 Non-woven fabric blended with 75% polyester fiber and 25% polypropylene fiber, 50% modulus 0.48kg/5c
A patch of the present invention was obtained by coating a plaster of the above composition on a support having a thickness of 1.5 m and a drape coefficient of 0.338 so that 17 g per sheet (140 x 100 mm) was applied and cut.
この貼付剤について実験例工および2に従って試験した
ところ、実施例1と同様の優れた性能を示した。When this adhesive patch was tested according to Experimental Examples 1 and 2, it showed excellent performance similar to that of Example 1.
(以下余白)
実施例3
組
ブフェキサマック
悲一メントール
クロタミトン
グリセリン
プロピレングリコール
酸化亜鉛
グリセリン脂肪酸エステル
合成ヒドロタルサイト
水
20.0
10、0
5.0
1.0
0.06
100。0
※l)
固形分として4.0%
ポリエステル98%、レーヨン繊維2%の混紡の不織布
で50%モジュラスが0.43kg/ 5 am、ドレ
ープ係数0.402の支持体に,上記組成の膏体を1枚
(60 X 60mm)当たり2gとなるように塗工、
裁断し、本発明の貼付剤を得た。(Left below) Example 3 Set Bufexamac Seiichi Menthol Crotamiton Glycerin Propylene Glycol Zinc oxide Glycerin Fatty acid ester Synthesis Hydrotalcite Water 20.0 10,0 5.0 1.0 0.06 100.0 *l) Solid One sheet of plaster of the above composition (60% Coating so that it is 2g per x 60mm),
It was cut to obtain a patch of the present invention.
この貼付剤について実験例1および2に従って試験した
ところ、実施例1と同様の優れた性能を示した。When this patch was tested according to Experimental Examples 1 and 2, it showed the same excellent performance as Example 1.
実施例4〜l1
下記表−3に示した組成の膏体を、不織布(50%モジ
ュラス、ドレープ係数は表−3中に記載)に塗工して本
発明の貼付剤を得た。Examples 4 to 11 A patch of the present invention was obtained by applying a plaster having the composition shown in Table 3 below to a nonwoven fabric (50% modulus, drape coefficient listed in Table 3).
これら貼付剤は、実施例1と同様に貼りやすく、剥がれ
にくく、密着性の点でも優れていた8(以下余白)Similar to Example 1, these patches were easy to apply, difficult to peel off, and had excellent adhesion (see margin below).
Claims (1)
持体部として、50%モジュラスが0.1〜2.0kg
/5cmであり、かつ、JIS一般織物試験法による剛
軟性がドレープ係数で0.200〜0.650である伸
縮性支持体を用いたことを特徴とする貼付剤。1. In a patch having a support part and a plaster part, the support part has a 50% modulus of 0.1 to 2.0 kg.
/5 cm, and has a drape coefficient of 0.200 to 0.650 according to the JIS general textile test method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30130089A JP2726948B2 (en) | 1989-11-20 | 1989-11-20 | Patch |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30130089A JP2726948B2 (en) | 1989-11-20 | 1989-11-20 | Patch |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03161432A true JPH03161432A (en) | 1991-07-11 |
JP2726948B2 JP2726948B2 (en) | 1998-03-11 |
Family
ID=17895180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP30130089A Ceased JP2726948B2 (en) | 1989-11-20 | 1989-11-20 | Patch |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2726948B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000319168A (en) * | 1999-05-12 | 2000-11-21 | Yuutoku Yakuhin Kogyo Kk | Local anesthetic tape preparation |
WO2001095889A1 (en) * | 2000-06-13 | 2001-12-20 | Hisamitsu Pharmaceutical Co., Inc. | Plaster |
JP2002193795A (en) * | 2001-11-02 | 2002-07-10 | Yuutoku Yakuhin Kogyo Kk | Local anesthetic tape |
EP1287824A4 (en) * | 2000-06-06 | 2004-07-14 | Teijin Ltd | Member for application of ointment and ointment patch employing the same |
-
1989
- 1989-11-20 JP JP30130089A patent/JP2726948B2/en not_active Ceased
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000319168A (en) * | 1999-05-12 | 2000-11-21 | Yuutoku Yakuhin Kogyo Kk | Local anesthetic tape preparation |
EP1287824A4 (en) * | 2000-06-06 | 2004-07-14 | Teijin Ltd | Member for application of ointment and ointment patch employing the same |
US7074421B2 (en) | 2000-06-06 | 2006-07-11 | Teijin Limited | Member for application of ointment and ointment patch employing the same |
WO2001095889A1 (en) * | 2000-06-13 | 2001-12-20 | Hisamitsu Pharmaceutical Co., Inc. | Plaster |
JP5038576B2 (en) * | 2000-06-13 | 2012-10-03 | 久光製薬株式会社 | Patch |
JP2002193795A (en) * | 2001-11-02 | 2002-07-10 | Yuutoku Yakuhin Kogyo Kk | Local anesthetic tape |
Also Published As
Publication number | Publication date |
---|---|
JP2726948B2 (en) | 1998-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022137110A (en) | Adhesive film bandage for medical compression | |
US11311423B2 (en) | Facial patch | |
JP2000502349A (en) | Drug delivery device | |
PT1269999E (en) | Ultraviolet-shielding patch | |
AU4907599A (en) | Topical plaster with non-steroidal antirheumatic agents with an acid group | |
PT1238664E (en) | Adhesive preparations | |
WO2006006656A1 (en) | Heating element | |
WO2012014589A1 (en) | Adhesive patch for medical use | |
JP5711742B2 (en) | Medical patch | |
JP5089933B2 (en) | Water-containing pressure-sensitive adhesive composition and patch using the same | |
CN101553257B (en) | Adhesive skin patch and method for evaluation of adhesive skin patch | |
JPH03161432A (en) | Cataplasm | |
JPH03161433A (en) | Cataplasm | |
JPS58174484A (en) | Pressure-sensitive adhesive tape or sheet | |
JP2007204393A (en) | Skin plaster | |
JP2879228B2 (en) | Elastic patch | |
JPH0613821U (en) | Medical tape | |
JP3207257B2 (en) | Patch | |
JPWO2020175395A1 (en) | Patch | |
JP7412905B2 (en) | patch | |
KR20220034030A (en) | Acrylic Polymers and Adhesive Compositions | |
JPH07284507A (en) | Thermopasting agent | |
JPH11349476A (en) | Medical pasting material | |
JP2887548B2 (en) | Hydrous skin external patch with improved usability | |
JPH03161434A (en) | Stretchable cataplasm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RVOP | Cancellation by post-grant opposition |